Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral detection is described for the determination of capecitabine, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine in human plasma with 5-chloro-2'-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500-10.0 microgram/ml for capecitabine, and 0.0500-25.0 microgram/ml for the metabolites, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin.
Xu
Yan
Y
Gastrointestinal Malignancies Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 20889-5105, Bethesda, MD, USA.
Grem
Jean L
JL
D000964:Antimetabolites, Antineoplastic / Q000097:blood* / Q000493:pharmacokinetics; D000069287:Capecitabine; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D015179:Colorectal Neoplasms / Q000097:blood; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000097:blood* / Q000493:pharmacokinetics; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil